Israeli diagnostics firm Sight Diagnostics had received clearance from the US Food and Drug Administration (FDA) for its Olo blood analyser, which can process results for a complete blood test in approximately ten minutes.

The test can process results with two drops of blood taken from either the finger or the veins. It calculates red blood cells, white blood cells and platelets in a blood sample.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Sight Diagnostics chief technical officer Sarah Levy was quoted by Reuters as saying: “This could be a big change because at the moment a traditional analyser can be placed in laboratories that run thousands of tests every week.”

A complete blood count (CBC) test not only provides a snapshot of a patient’s health but can also be used to identify leukaemia.

Approval from the FDA is expected to cut costs at laboratories with lower blood volumes.

Conventional CBC tests use flow cytometry technology, which requires personnel for maintenance of the device. Furthermore, the standard procedure takes up to a day to process results.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Digitising blood samples into images, the device uses algorithms to interpret and process results in minutes.

Following approval, Sight, which also has a device for identifying malaria, is expected to compete with Quest Diagnostics and Laboratory Corp of America Holdings, a significant player in the diagnostics market, reported the news agency.

Outside the US, the Israeli startup sells its device in private and public hospitals, pharmacies and outpatient clinics across Asia, Europe, South America, Australia and Africa.

In February, Sight raised almost $28m in a Series C funding round. With this round, it raised a total of $50m.